BMRN FINANCIAL STATEMENTS

Biomarin Pharmaceutical Inc — balance sheet, income statement and cash flow trends

BMRNBiomarin Pharmaceutical Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue3.2 B $+9.9%

Gross Profit2.5 B $+5.1%

Operating Income439.2 M $-29.1%

EBITDA482.5 M $-37.9%

Net Income268.7 M $-48.7%

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
BMRN	9.9%	75.9%	14.9%	8.3%
CSL	4.8%	48.6%	32.8%	9.2%
TLX	56.3%	50.8%	3.0%	-0.9%
MSB	410.4%	-32.0%	-76.6%	-115.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
BMRN	9.9%	75.9%	14.9%	8.3%
KRYS	25.1%	92.8%	48.1%	53.9%
ARWR	9.4%	100.0%	-21.6%	-48.4%
TECH	0.2%	65.0%	21.3%	9.0%
KYMR	-12.6%	100.0%	-594.7%	-612.2%
AXSM	63.9%	92.6%	-24.4%	-26.6%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity6.2 B $72%
Current Liabilities793.2 M $9%
Long-term Liabilities1.6 B $18%

Key Figures

YoY change

Total Assets8.6 B $+20.2%

Total Liabilities2.4 B $+75.8%

Total Equity6.2 B $+7.2%

Cash & ST Investments2.2 B $+74.7%

Total Debt1.4 B $+139.2%

Net Debt-782.8 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
BMRN	5.81	23.2%	-1.62	72.3%
CSL	2.57	67.4%	2.22	49.2%
TLX	1.43	112.3%	13.13	35.1%
MSB	—	—	—	—
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
BMRN	5.81	23.2%	-1.62	72.3%
KRYS	9.46	0.7%	-4.06	91.4%
ARWR	6.23	223.7%	3.06	27.1%
TECH	4.49	13.9%	0.31	81.8%
KYMR	10.81	5.2%	1.86	92.2%
AXSM	1.39	402.8%	0.49	7.6%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow874.3 M $+24.8%

Capital Expenditures107.2 M $+33.9%

Free Cash Flow767.1 M $+23.7%

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
BMRN	27.0%	23.7%	3.3%	325.3%
CSL	24.0%	20.3%	3.7%	261.5%
TLX	-2.2%	-6.3%	4.1%	243.1%
MSB	-87.7%	-90.0%	2.3%	76.1%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
BMRN	27.0%	23.7%	3.3%	325.3%
KRYS	60.0%	56.9%	3.1%	111.2%
ARWR	-5.8%	-8.2%	2.3%	12.1%
TECH	24.4%	22.3%	2.1%	269.1%
KYMR	-471.4%	-474.1%	2.8%	77.0%
AXSM	-10.0%	-10.0%	0.0%	37.6%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on BMRN

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.